Triple-negative breast cancer (TNBC) - closeup view 3d illustration] Nemes Laszlo/iStock via Gilead Sciences (NASDAQ:GILD [ announced Saturday that its antibody-drug conjugate Trodelvy, in ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces a proposed consolidation of the ...

The marriage comes at a significant time in Hina’s life. In June 2024, she was diagnosed with Stage 3 breast cancer.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, ...

BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in ...

In partnership with Veterans of Foreign Wars (VFW) and the Disabled American Veterans (DAV), Grunt Style Foundation will host the "War Cry For Change" ? Veteran Harm Reduction Summit, June 4-5, 2025, ...

The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC, May 29, 2025 /PRNewswire/ ...

Hina Khan married her longtime boyfriend, Rocky Jaiswal, a successful television producer and businessman. Their love story ...

Summit Therapeutics Inc. has recently reported positive topline results from the phase III clinical trial, Harmoni, ...

The issuance of 18 patents and patent applications internationally strengthens CERo Therapeutics' intellectual property portfolio, providing a competitive edge in the immunotherapy market.

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response ...

At the time, Brahmer was a principal investigator in a phase 3 clinical trial at Johns Hopkins Hospital for nivolumab, an immunotherapy known as an anti-PD1 drug. The trial built on years of National ...